Clinical Scorecard: Association of Neuropsychiatric Symptoms with Progression to Pathologically Diagnosed Alzheimer’s Disease
At a Glance
Category
Detail
Condition
Alzheimer’s disease and related neurodegenerative dementias
Key Mechanisms
Mild behavioural impairment (MBI) as a marker of later-life emergent and persistent neuropsychiatric symptoms (NPS) associated with AD pathology; neuropathological changes including AD neuropathological change (ADNC), Lewy body disease (LBD), and TDP-43 proteinopathy
Target Population
Older adults without dementia at baseline, including those with normal cognition and mild cognitive impairment
Care Setting
Research and clinical settings focused on early identification and management of neurodegenerative disease
Key Highlights
MBI+ status (persistent NPS) is strongly associated with post-mortem AD pathology but not with LBD or TDP-43 pathology.
MBI+ individuals have a twofold greater progression rate to AD dementia compared to those without NPS, with a stronger effect in cognitively normal individuals.
Limbic LBD moderates the association between MBI and incident AD dementia, increasing progression risk.
Guideline-Based Recommendations
Diagnosis
Consider incorporating MBI criteria to identify individuals at high risk for progression to AD dementia.
Use persistent later-life emergent NPS (MBI) as a clinical marker alongside cognitive assessments for early detection of AD pathology.
Management
Monitor individuals with MBI closely for cognitive decline and progression to dementia.
Include MBI assessment in patient selection for AD-modifying treatments.
Monitoring & Follow-up
Regularly assess neuropsychiatric symptoms persistence over time to distinguish MBI from transient or non-prodromal NPS.
Monitor cognitive status progression in MBI+ individuals, especially those with normal cognition or mild cognitive impairment.
Risks
MBI+ status indicates increased risk of progression to AD dementia.
Comorbid pathologies such as limbic LBD may further increase progression risk.
Patient & Prescribing Data
Older adults with persistent later-life emergent neuropsychiatric symptoms (MBI), including those with normal cognition and mild cognitive impairment.
MBI identification may aid in selecting patients for AD-modifying therapies by identifying early-stage neurodegenerative disease.
Clinical Best Practices
Operationalize MBI as persistent NPS present in more than two-thirds of pre-dementia visits to improve prognostic accuracy.
Distinguish MBI from long-standing psychiatric symptoms by focusing on later-life onset and persistence.
Incorporate neuropathological findings and biomarker data (amyloid-β, tau, APOE ɛ4) alongside MBI assessment for comprehensive risk evaluation.
Recognize the additive effects of co-pathologies such as LBD and TDP-43 in dementia progression.
